Vericel Corp
Vericel Corp is a U.S.-based biopharmaceutical company focused on advanced therapies for cartilage repair and severe burn care. Its commercial portfolio includes MACI for knee cartilage defects, Epicel for severe burns, and NexoBrid for burn eschar removal in North America through a license and supply arrangement.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueAutologous cell therapy for repair of symptomatic knee cartilage defects.
Cultured epidermal autograft used for patients with severe burns.
Specialty biologic for enzymatic removal of burn eschar in burn care.
Arthroscopic delivery tools and accessories used with MACI implants.
Customers
Vericel sells primarily to hospitals, specialty pharmacies, burn centers, and surgeons that treat patients with cartilage injuries or severe burns. MACI is used by orthopedic surgeons and reimbursed through commercial, government, or hospital channels, while Epicel and NexoBrid are directed to burn centers and hospital-based care teams. The business depends on physician adoption, payer coverage, and institutional purchasing decisions.
Buy and implant MACI for symptomatic knee cartilage defects, especially higher-volume arthroscopic surgeons.
Dispense MACI under payer authorization and manage billing/collection for patient-specific use.
Use Epicel and NexoBrid for severe burn treatment and eschar removal.
Purchase NexoBrid and resell it to hospitals and burn centers.
Buy MACI under contracted arrangements for treatment at military facilities.
Strategy
Vericel’s strategy centers on expanding adoption of its commercial therapies, especially MACI, while broadening surgeon access through MACI Arthro. It also seeks to grow burn care through Epicel and NexoBrid, supported by focused sales teams, payer coverage, and manufacturing scale-up in Massachusetts.
MACI is the core commercial product and depends on surgeon training and procedural penetration.
Burn care provides a second specialty channel with focused institutional customers.
Cell therapy products require reliable in-house production and validated facilities.
Geography
Vericel’s operations are concentrated in the United States, where it manufactures, markets, and sells its products. The company states that all operations are located in the U.S. and that 100% of revenue is derived from domestic sales, making its business highly dependent on U.S. reimbursement, regulation, and hospital purchasing patterns.
Risks
Vericel faces concentration risk in a small number of specialty products, with demand tied to surgeon adoption, burn-center utilization, and payer coverage. Its cell-therapy manufacturing model also creates operational and regulatory risk, while NexoBrid commercialization depends on maintaining licensed rights and achieving market acceptance in the U.S.
- Manufacturing disruption or facility failureImpact: CriticalLikelihood: Medium
Products are biologic therapies requiring controlled in-house production and supply continuity.
Exposure: MACI and Epicel manufacturing in Massachusetts
- Quarterly and annual revenue volatilityImpact: HighLikelihood: Medium
Sales depend on procedure timing, seasonal patterns, and burn-care demand.
Exposure - Payer coverage and reimbursement riskImpact: HighLikelihood: Medium
MACI shipments require prior authorization and reimbursement can vary by payer.
Exposure: MACI
- Intellectual property and license dependenceImpact: HighLikelihood: Low
Exclusive commercialization rights for NexoBrid depend on compliance with MediWound agreements.
Exposure: NexoBrid
- Commercial adoption risk for NexoBridImpact: MediumLikelihood: Medium
The product must gain acceptance in a specialized burn-care market to scale meaningfully.
Exposure: North America commercialization rights
- Competition from alternative cartilage and burn treatmentsImpact: MediumLikelihood: Medium
Established medical device and biologics companies compete in regenerative medicine and burn care.
Exposure: MACI and Epicel
Accounting
Judgemental itemsRevenue is recognized at delivery, but net revenue depends on estimated allowances and expected collections.
Impact: Patient-specific reimbursement and denial rates affect reported sales
MACI sold through specialty pharmacies requires estimates of amounts not expected to be collected.
Impact: Can materially change net product revenue and receivables
Manufacturing and office leases create amortization and liability recognition under U.S. GAAP.
Impact: Affects operating expenses and balance sheet obligations
Management cites cumulative losses and forecasts in assessing realizability.
Impact: Can significantly affect tax expense and net income
Similar listed companies
Publicly listed companies with a comparable business focus.
MediWound Ltd.
MDWD · Medicinal Chemicals & Botanical Products
NexGel, Inc
NXGL · Surgical & Medical Instruments & Apparatus
Mesoblast Limited
MESO · Biological Products, (No Diagnostic Substances)
Mesoblast Ltd is a biopharmaceutical company focused on developing and commercializing allogeneic cell therapies based on mesenchymal stromal cells.
Hexcel Corporation
HXL · Plastic Materials, Synth Resins & Nonvulcan Elastomers
Hexcel Corp.
Nurix Therapeutics, Inc.
NRIX · Pharmaceutical Preparations
Nurix Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing targeted protein degradation medicines.
Axogen, Inc.
AXGN · Electromedical & Electrotherapeutic Apparatus
Last updated: 24/09/2026